Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

Secondary Lymphoid Organs

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...

Lymphoid Cells and Tissues

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.

The American journal of gastroenterology·2018

Same author

Individualized lung recruitment maneuver guided by pulse-oximetry in anesthetized patients undergoing laparoscopy: a feasibility study.

Acta anaesthesiologica Scandinavica·2018

Same author

Erratum: Observation of the hyperfine spectrum of antihydrogen.

Nature·2017

Same author

Correlates of ideal cardiovascular health in European adolescents: The HELENA study.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2017

Same author

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Antihydrogen accumulation for fundamental symmetry tests.

Nature communications·2017

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Diffuse large B-cell lymphoma in the older.

A Gutiérrez¹, F Mestre, G Pérez-Manga

¹Service of Hematology, University Hospital Son Dureta, Palma de Mallorca, Spain.

Critical Reviews in Oncology/Hematology

|March 23, 2010

Summary

This summary is machine-generated.

Diffuse large B-cell lymphoma (DLCL) is a growing concern in older adults. While treatment response is similar, older patients face higher toxicity and relapse rates, necessitating tailored therapeutic strategies.

Related Experiment Videos

Last Updated: Jun 14, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

Oncology
Geriatric Medicine
Hematology

Background:

Diffuse large B-cell lymphoma (DLCL) incidence is rising in older populations, posing a significant future health challenge.
Tumor biology and prognostic factors in DLCL show minimal differences between younger and older patient groups.

Purpose of the Study:

To analyze the key differences between young and older DLCL patients regarding immunologic status, treatment toxicity, and comorbidities.
To review clinical studies to inform optimal DLCL therapy decisions for the elderly population.

Main Methods:

Comparative analysis of DLCL patient populations (young vs. older).
Review of existing clinical studies on DLCL treatment in elderly patients.
Evaluation of factors including immunologic status, treatment tolerance, and organ function.

Main Results:

Older DLCL patients exhibit similar response rates to chemotherapy as younger patients when appropriate doses are given.
However, older patients demonstrate lower treatment tolerance and a higher relapse rate even after initial response.

Conclusions:

Despite similar initial responses, age-related factors like reduced tolerance and increased relapse necessitate specialized approaches for DLCL treatment in older adults.
Further research and clinical decision-making should prioritize addressing these age-specific challenges in DLCL management.